



15 February 2022

Clarifying Statement in relation to Opyl's quarterly activities report for the period ended 31 December 2021 – Quarter (Q2)

Melbourne, Australia – Opyl Limited (ASX:OPL) advises that in accordance with Listing Rule 4.7C.1 the company is required to describe in its quarterly activities report (lodged with the ASX on 28 January 2022) details of its business activities for the quarter. It therefore provides a clarifying announcement of these activities for the quarter ended 31 December 2021 to provide more detail and should be read in conjunction with the December 2021 Quarterly Business Update and Appendix 4C lodged with the ASX on 28 January 2022.

Highlights

In relation to the contracts executed by Opyl in the December Quarter for Insights projects, Opyl confirms that these contracts are not material. Although not material individually, these contracts have the potential to grow.

Opyl and RMIT Innovations Connect Grant

The Innovation Connections Grant is for \$50K payable to RMIT University, School of Computing Technologies to subsidise Opyl's cost for a data science researcher placement for a 12 month period in collaboration with RMIT University to assist the company in continuing its development of Opin. This reduces the cost to the business to \$57K over the 12 month period.

Financials

The Director Fees for the December quarter disclosed in the quarterly activities report were inadvertently reported incorrectly. The amount for the quarter was \$51K rather than \$55K as stated.

The Board has authorised this announcement for release to the ASX.

-ENDS-

For media enquiries: Laura Blue +61 416 699 925

For investor enquiries: info@opyl.ai

www.opyl.ai

Opyl is a new generation Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare design, development, and delivery.

Opyl works at the intersection of clinical trials, artificial intelligence, and social media.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions
- clinical trial predictive analytics and protocol design
- deep social media insights and analysis

Our vision is to improve health and wellness by optimising data assets and digital activation to advance technologies for life.

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook